Project Grant R44AG091827
Award Date 9/20/25
Completion Date 5/31/27
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- This Project Grant award was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The goal of the project is to test whether a new humanized monoclonal antibody (ADWA11) can restore microglia-astrocyte responses as a therapy for Alzheimer's disease (AD). The $254,896 award to Glial Therapeutics, LLC will support research to understand how pharmacological inhibition of the ITGB8 integrin can modulate microglia phenotype and function to...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $479,375 to Florida International University to conduct research on the effect of a small molecule activator of autophagy, TPI-132, on insulin signaling, senescence, and neuropathology in mouse models of Alzheimer's disease. The goal is to optimize TPI-132 to increase its potency, brain penetration, and reduce toxicity, and then evaluate its impacts on neuronal senescence, synapses, protein...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded Aivocode, Inc. a $1,244,775 project grant to develop single domain antibodies targeting Connective Tissue Growth Factor (CTGF) for improving vascular dysfunction in Alzheimer's disease. The award period runs from September 2025 to May 2027. The funding will support preclinical research to test these single domain antibodies in mouse models of Alzheimer's disease, with the goal of...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
- The National Institute on Aging (NIA) awarded a $842,175 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on December 15, 2024, will fund research to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies, including network hyperactivity, glucose hypometabolism, and accumulation of amyloid-beta and tau proteins. The research aims to assess the therapeutic efficacy of a novel...
- This Phase I Small Business Technology Transfer (STTR) grant from the National Institute on Aging (CFDA 93.866 - Aging Research) is supporting research by Alphamemory, LLC to target the substrate of gamma-secretase for selective amyloid reduction in Alzheimer's disease. The $252,124 award, effective September 20, 2025, will fund initial structure-activity relationship studies of a lead compound (C1) and in vivo pharmacokinetic and pharmacodynamic characterization of preclinical candidates. The...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
- The National Institute on Aging (NIA) awarded a $442,357 Project Grant under the Aging Research program (CFDA 93.866) to the Research Foundation of the City University of New York (RFCUNY) on December 15, 2024. The grant aims to elucidate the molecular mechanisms that give rise to functionally neurodegenerative microglia, the brain's primary innate immune cells, which have been implicated as major determinants of Alzheimer's disease (AD) risk. The research will leverage novel mouse models and...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
- The U.S. National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $2,329,970 Project Grant to the University of Florida to conduct research on "Evaluation of the Neuroimmune Mechanisms Influencing Therapeutic Targeting Potential of the LH/CG Receptor in the Menopausal and AD Brain". This 4-year project, running from September 1, 2025 to August 31, 2029, seeks to investigate the potential immune-regulating role of the LH/CG receptor...